Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 99 | 1.970 |
Why?
|
| Dyslipidemias | 4 | 2017 | 107 | 1.690 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 99 | 1.530 |
Why?
|
| Lipids | 4 | 2014 | 275 | 1.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 377 | 1.350 |
Why?
|
| Atherosclerosis | 5 | 2016 | 259 | 1.040 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 367 | 0.990 |
Why?
|
| Carotid Arteries | 4 | 2018 | 135 | 0.990 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 39 | 0.780 |
Why?
|
| HIV Infections | 2 | 2020 | 850 | 0.670 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 60 | 0.670 |
Why?
|
| Cause of Death | 1 | 2020 | 269 | 0.640 |
Why?
|
| Heart Sounds | 1 | 2017 | 1 | 0.580 |
Why?
|
| American Heart Association | 1 | 2017 | 95 | 0.560 |
Why?
|
| Primary Prevention | 1 | 2017 | 82 | 0.540 |
Why?
|
| Cyclin D1 | 1 | 2016 | 84 | 0.520 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 252 | 0.520 |
Why?
|
| Pericardium | 1 | 2016 | 70 | 0.510 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 154 | 0.500 |
Why?
|
| Guideline Adherence | 1 | 2017 | 234 | 0.500 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 18 | 0.490 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 141 | 0.490 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 117 | 0.450 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 716 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1284 | 0.440 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 169 | 0.440 |
Why?
|
| Adipose Tissue | 1 | 2016 | 262 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3480 | 0.430 |
Why?
|
| Azetidines | 2 | 2016 | 37 | 0.430 |
Why?
|
| Thrombosis | 2 | 2015 | 302 | 0.430 |
Why?
|
| Heart Diseases | 1 | 2015 | 302 | 0.410 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 39 | 0.410 |
Why?
|
| Jejunum | 1 | 2012 | 80 | 0.400 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 125 | 0.390 |
Why?
|
| Heart Ventricles | 1 | 2017 | 786 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 608 | 0.390 |
Why?
|
| Hypertension | 1 | 2017 | 745 | 0.370 |
Why?
|
| MicroRNAs | 1 | 2016 | 556 | 0.370 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 168 | 0.370 |
Why?
|
| Disease Progression | 4 | 2020 | 1468 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1055 | 0.350 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 226 | 0.320 |
Why?
|
| Blood Glucose | 1 | 2012 | 837 | 0.310 |
Why?
|
| Middle Aged | 14 | 2020 | 26179 | 0.290 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.280 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 7 | 0.280 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 97 | 0.270 |
Why?
|
| Humans | 24 | 2021 | 90014 | 0.260 |
Why?
|
| Male | 15 | 2020 | 42705 | 0.230 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.220 |
Why?
|
| Risk Factors | 4 | 2020 | 5566 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2018 | 8295 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 275 | 0.200 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 359 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3682 | 0.190 |
Why?
|
| Biomarkers | 4 | 2018 | 1779 | 0.190 |
Why?
|
| Incidence | 3 | 2015 | 1604 | 0.180 |
Why?
|
| Heart Transplantation | 1 | 2006 | 733 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1670 | 0.170 |
Why?
|
| Time Factors | 4 | 2018 | 5362 | 0.170 |
Why?
|
| Coronary Angiography | 2 | 2012 | 244 | 0.160 |
Why?
|
| Female | 11 | 2020 | 46620 | 0.150 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 30 | 0.150 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 846 | 0.150 |
Why?
|
| Compliance | 1 | 2017 | 21 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 885 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 45 | 0.140 |
Why?
|
| Chest Pain | 1 | 2017 | 42 | 0.140 |
Why?
|
| Heart Failure | 1 | 2006 | 1255 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.130 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 25 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 422 | 0.130 |
Why?
|
| Melanocytes | 1 | 2016 | 57 | 0.130 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 95 | 0.130 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 26 | 0.130 |
Why?
|
| Immunoblotting | 1 | 2016 | 272 | 0.130 |
Why?
|
| Adult | 8 | 2018 | 26845 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 21 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 983 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1134 | 0.120 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 73 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2016 | 508 | 0.110 |
Why?
|
| Cisplatin | 1 | 2016 | 598 | 0.110 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 71 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1081 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 280 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2020 | 2886 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 511 | 0.110 |
Why?
|
| Pyrroles | 2 | 2011 | 172 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1718 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2327 | 0.100 |
Why?
|
| Ezetimibe | 1 | 2012 | 35 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 785 | 0.100 |
Why?
|
| Simvastatin | 2 | 2016 | 105 | 0.100 |
Why?
|
| Melanoma | 1 | 2016 | 470 | 0.100 |
Why?
|
| Cell Line | 1 | 2016 | 2495 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 625 | 0.090 |
Why?
|
| Global Health | 1 | 2013 | 193 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2588 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1869 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1879 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2016 | 1670 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 28 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 19269 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 69 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 256 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2328 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1714 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 164 | 0.060 |
Why?
|
| United States | 1 | 2017 | 7115 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 27551 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 1083 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1731 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 201 | 0.040 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 29 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 128 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 137 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 20 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 233 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 67 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 323 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 55 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 12 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 283 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 294 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 146 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 417 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 793 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 376 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 163 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 99 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 853 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 740 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 557 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 463 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1122 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 961 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 258 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 241 | 0.030 |
Why?
|
| Idaho | 1 | 2011 | 8 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 35 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 49 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 521 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 210 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4326 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2887 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 806 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 236 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2026 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 953 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1395 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 11 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6784 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1180 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2360 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3406 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2310 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2317 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 4169 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11869 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2769 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 300 | 0.010 |
Why?
|